|
Jul 25
|
Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?
|
|
Jul 15
|
Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?
|
|
May 10
|
Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 9
|
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 9
|
Q1 2024 Karyopharm Therapeutics Inc Earnings Call
|
|
May 8
|
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
|
|
May 8
|
Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review
|
|
May 8
|
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
|
|
May 8
|
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
|
|
May 2
|
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
|
|
Apr 24
|
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
|
|
Mar 6
|
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
|
|
Mar 5
|
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
|
|
Feb 7
|
Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%
|
|
Dec 6
|
Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous year
|
|
Dec 1
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 8
|
Karyopharm to Participate at Upcoming Investor Conferences
|
|
Nov 6
|
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
|